Compare AbCellera Biologics Inc (ABCL) vs TJX Companies Inc (TJX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs TJX Companies Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while TJX Companies Inc trades at $153.18 (market cap $170.25B). The key difference: TJX Companies Inc is far larger — about 72.4× AbCellera Biologics Inc's market cap, and TJX Companies Inc pays a 1.25% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TJX | |
|---|---|---|
Market Cap | $2.35B | $170.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $168.41 |
52-Week Low | $2.78 | $121.35 |
Enterprise Value | $1.99B | $178.85B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TJX trades at $154.11, up slightly by 0.02% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate, and maintains robust profitability with a 61.25% ROE. Revenue growth is steady, reaching $56.36B in 2025, supported by expansion in home goods and international markets.
Outlook remains positive with an 88% analyst buy rating and a $181.80 consensus price target, implying 18% upside. Risks include high valuation multiples like a 29.44 P/E and economic sensitivity, but strong cash flow and dividend payments provide stability. Investors should monitor Q2 2026 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
